31 Mar Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis
Since November 2019, the rapid outbreak of coronavirus disease 2019 (Covid-19), which arose from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become a public health emergency on a global level. Covid-19 has contributed to an enormous adverse impact globally and the situation is evolving rapidly. A recent study has evaluated the risk of serious adverse outcomes in patients with Covid-19 by stratifying the comorbidity status.
The study, published in the European Respiratory Journal, assessed 1590 laboratory-confirmed patients from 575 hospitals across mainland China from December 11th 2019 to January 31st 2020. Analysis consisted of composite endpoints including admission to intensive care, invasive ventilation or death. These composite endpoints were compared according to the presence and number of comorbidities.
The mean age was 48.9 years. 686 patients (42.7%) were females. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD [hazards ratio (HR) 2.681, 95% confidence interval (95%CI) 1.424–5.048], diabetes (HR 1.59, 95%CI 1.03–2.45), hypertension (HR 1.58, 95%CI 1.07–2.32) and malignancy (HR 3.50, 95%CI 1.60–7.64) were risk factors of reaching to the composite endpoints. The HR was 1.79 (95%CI 1.16–2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61–4.17) among patients with two or more comorbidities.
Among laboratory-confirmed cases of Covid-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.
Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis
Wei-jie Guan, Wen-hua Liang, Yi Zhao, Heng-rui Liang, Zi-sheng Chen, Yi-min Li, Xiao-qing Liu, Ru-chong Chen, Chun-li Tang, Tao Wang, Chun-quan Ou, Li Li, Ping-yan Chen, Ling Sang, Wei Wang, Jian-fu Li, Cai-chen Li, Li-min Ou, Bo Cheng, Shan Xiong, Zheng-yi Ni, Jie Xiang, Yu Hu, Lei Liu, Hong Shan, Chun-liang Lei, Yi-xiang Peng, Li Wei, Yong Liu, Ya-hua Hu, Peng Peng, Jian-ming Wang, Ji-yang Liu, Zhong Chen, Gang Li, Zhi-jian Zheng, Shao-qin Qiu, Jie Luo, Chang-jiang Ye, Shao-yong Zhu, Lin-ling Cheng, Feng Ye, Shi-yue Li, Jin-ping Zheng, Nuo-fu Zhang, Nan-shan Zhong, Jian-xing He
European Respiratory Journal Jan 2020, 2000547; DOI: 10.1183/13993003.00547-2020